Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.

Journal of hepatology·2026
Same author

Dietary Guidelines 2025-2030 For Americans Are Concerning For Liver Health.

The American journal of gastroenterology·2026
Same author

Alcohol-Related Liver Disease: A Review.

JAMA·2026
Same author

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

JHEP reports : innovation in hepatology·2026
Same author

Counterfactual Diffusion Models Provide Interpretable Explanations of Artificial Intelligence Models in Pathology.

Cancer research·2026
Same author

Response to "Refining FIB-4-based risk stratification in adverse drug reactions".

European journal of clinical pharmacology·2026

Related Experiment Video

Updated: Jun 17, 2026

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Laurens A van Kleef1, Jesse Pustjens1, Carolin V Schneider2

  • 1Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Gastroenterology
|June 15, 2026
PubMed
Summary

Current fibrosis screening guidelines are too broad. A refined strategy significantly narrows eligibility to 10-22% of adults, increasing disease detection while minimizing unnecessary screenings.

Keywords:
EpidemiologyLiver FibrosisRisk StratificationScreening

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Area of Science:

  • Hepatology
  • Public Health
  • Diagnostic Criteria

Background:

  • Current fibrosis screening indicators encompass a large population, straining healthcare resources.
  • There is a need to evaluate and refine existing fibrosis screening criteria.

Purpose of the Study:

  • To evaluate and refine indicators for liver fibrosis screening.
  • To develop more targeted and efficient screening strategies.

Main Methods:

  • Utilized NHANES 2017-2020 data for adults aged 18-80 with BMI ≥18.5kg/m² and no excessive alcohol use.
  • Developed refined screening criteria targeting subgroups with ≥10% risk of liver stiffness measurement (LSM) ≥8kPa.
  • Validated refined criteria in general-population cohorts and linked to liver-related events.

Main Results:

  • Current guidelines identify 60-76% of adults for screening; refined criteria target 10-22%.
  • Refined strategy increased LSM ≥8kPa prevalence among eligible individuals from 11-14% to 28%.
  • In UK-Biobank, individuals meeting refined criteria showed a ~6-fold higher risk of incident cirrhosis and liver-related death.

Conclusions:

  • Refined fibrosis screening criteria significantly reduce the proportion of adults eligible for screening (10-22% vs. 60-76%).
  • The refined strategy achieves higher disease prevalence among screened individuals.
  • This approach maintains a very low risk of increased LSM or liver-related events in those not eligible for screening.